This article is more than 5 years old. Information may no longer be current.

Ophthalmology week in review

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are some recent top articles on Healio.com/OSN:

FDA accepts NDA for loteprednol etabonate ophthalmic gel 0.38%

A new drug application for Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel 0.38% has been accepted by the FDA. Read more.

FDA clears Alleye AMD monitoring application

Alleye is designed to detect and monitor age-related macular degeneration and characterize central and paracentral metamorphopsia. Read more.

Women in Ophthalmology Summer Symposium to focus on scientific innovations, burnout and leadership skills

The Women in Ophthalmology 2018 Summer Symposium will take place in Ponte Vedra Beach, Florida, from Aug. 16 to 19 and will focus on scientific innovations, wellness, leadership skills and self-care. Read more.

In phase 1 study, ICON-1 intravitreal injections safe in eyes with neovascular AMD

Intravitreal injections of ICON-1 in eyes with neovascular age-related macular degeneration were found to be safe and well-tolerated in doses up to 300 µg. Read more.

Oyster Point ’ s dry eye treatment shows positive phase 2b trial results

Oyster Point Pharma’s dry eye disease treatment met both sign and symptom primary endpoints in a phase 2b clinical trial. Read more.